Display options
Cite
Sømhovd M, Hagen E, Bergly T, et al. The Montreal Cognitive Assessment as a predictor of dropout from residential substance use disorder treatment. Heliyon. 2019;5(3):e01282doi: 10.1016/j.heliyon.2019.e01282.
Sømhovd, M., Hagen, E., Bergly, T., & Arnevik, E. A. (2019). The Montreal Cognitive Assessment as a predictor of dropout from residential substance use disorder treatment. Heliyon, 5(3), e01282. https://doi.org/10.1016/j.heliyon.2019.e01282
Sømhovd, Mikael, et al. "The Montreal Cognitive Assessment as a predictor of dropout from residential substance use disorder treatment." Heliyon vol. 5,3 (2019): e01282. doi: https://doi.org/10.1016/j.heliyon.2019.e01282
Sømhovd M, Hagen E, Bergly T, Arnevik EA. The Montreal Cognitive Assessment as a predictor of dropout from residential substance use disorder treatment. Heliyon. 2019 Mar 07;5(3):e01282. doi: 10.1016/j.heliyon.2019.e01282. eCollection 2019 Mar. PMID: 31025003; PMCID: PMC6476942.
Copy Download .nbib Format: NLM
Share it on

Heliyon. 2019 Mar 07;5(3):e01282. doi: 10.1016/j.heliyon.2019.e01282. eCollection 2019 Mar.

The Montreal Cognitive Assessment as a predictor of dropout from residential substance use disorder treatment.

Heliyon

Mikael Sømhovd, Egon Hagen, Tone Bergly, Espen Ajo Arnevik

Affiliations

  1. The Tyrili Foundation, Norway.
  2. KORFOR, Norway.
  3. National Advisory Unit on SUD Treatment, Oslo University Hospital, Norway.

PMID: 31025003 PMCID: PMC6476942 DOI: 10.1016/j.heliyon.2019.e01282

Abstract

BACKGROUND: Cognitive function is a challenge for many SUD patients, and residential SUD treatment is cognitively demanding. Treatment retention is a predictor for success in SUD treatment, and the literature links low cognitive function to increased dropout rates. In our study we investigate cognitive function and dropout in a residential SUD treatment setting, also accounting for psychological distress.

METHODS: We screened a cohort (N = 142) of inpatients for cognitive function (MoCA®) and psychological distress (SCL-10) and calculated the relative risk for dropping out if over versus under the respective cut-off values (<26 and >1.85), and sex, and age-group (<23 years). We also employed a logistic regression with dropout as outcome and MoCA- and SCL-10 scores, and age and days before testing as input.

RESULTS: Dropout risk was higher (RR = 1.70) if scoring below MoCA cut-off, and for those younger than 23 years (RR = 2.36). The other variables did not influence dropout risk. MoCA raw scores, age, and SCL-10 were associated with dropout (p < .05); with lower symptoms of psychological distress predicting increased dropout. The interaction between MoCA and SCL-10 scores was not significant (p = .26).

CONCLUSIONS: SUD patients should routinely be screened for cognitive impairment, as it predicts dropout. Screenings should be ensued by appropriate adaptations to treatment and further assessment. The MoCA is a useful screening tool for this, independent of psychological distress. Future studies should replicate our findings, investigate specific interventions, and establish SUD population norms for the MoCA.

Keywords: Clinical psychology; Psychology; Rehabilitation

References

  1. Addict Behav. 1999 May-Jun;24(3):449-53 - PubMed
  2. Br J Psychiatry. 2000 Jul;177:4-7 - PubMed
  3. Arch Neurol. 2001 Dec;58(12):1985-92 - PubMed
  4. J Psychiatr Res. 1975 Nov;12(3):189-98 - PubMed
  5. Exp Clin Psychopharmacol. 2002 Aug;10(3):193-212 - PubMed
  6. Nord J Psychiatry. 2003;57(2):113-8 - PubMed
  7. Drug Alcohol Depend. 2003 Aug 20;71(2):207-11 - PubMed
  8. J Am Geriatr Soc. 2005 Apr;53(4):695-9 - PubMed
  9. Drug Alcohol Depend. 2006 Feb 28;81(3):313-22 - PubMed
  10. Lancet. 2006 Apr 15;367(9518):1262-70 - PubMed
  11. Psychol Addict Behav. 2006 Sep;20(3):241-53 - PubMed
  12. Exp Clin Psychopharmacol. 2008 Dec;16(6):484-97 - PubMed
  13. Exp Clin Psychopharmacol. 2009 Oct;17(5):337-44 - PubMed
  14. Neurology. 2009 Nov 24;73(21):1738-45 - PubMed
  15. Neurosci Biobehav Rev. 2011 Jan;35(3):377-406 - PubMed
  16. Am J Addict. 2012 Jan-Feb;21(1):78-85 - PubMed
  17. Clin Psychol Rev. 2013 Dec;33(8):1010-24 - PubMed
  18. Alzheimers Dement (Amst). 2015 Jun 28;1(3):289-94 - PubMed
  19. J Subst Abuse Treat. 2017 May;76:81-87 - PubMed
  20. J Clin Exp Neuropsychol. 2018 Mar;40(2):107-122 - PubMed
  21. Qual Soc Work. 2018 Jan;17(1):24-40 - PubMed
  22. Subst Abuse. 2018 Feb 28;12:1178221818760551 - PubMed
  23. J Dual Diagn. 2018 Sep 5;:1-9 - PubMed
  24. J Clin Psychol. 1987 May;43(3):395-403 - PubMed
  25. J Psychoactive Drugs. 1986 Jul-Sep;18(3):203-8 - PubMed
  26. Psychopharmacol Bull. 1973 Jan;9(1):13-28 - PubMed
  27. J Consult Clin Psychol. 1978 Dec;46(6):1187-91 - PubMed
  28. J Stud Alcohol. 1980 Jan;41(1):147-55 - PubMed
  29. J Consult Clin Psychol. 1997 Oct;65(5):789-802 - PubMed

Publication Types